Windlas Biotech Limited (BOM:543329)
816.55
+8.30 (1.03%)
At close: Jun 19, 2026
Windlas Biotech Revenue
In the fiscal year ending March 31, 2026, Windlas Biotech had annual revenue of 9.04B INR with 18.98% growth. Windlas Biotech had revenue of 2.38B in the quarter ending March 31, 2026, with 17.66% growth.
Revenue
9.04B
Revenue Growth
+18.98%
P/S Ratio
1.86
Revenue / Employee
n/a
Employees
1,346
Market Cap
16.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 9.04B | 1.44B | 18.98% |
| Mar 31, 2025 | 7.60B | 1.29B | 20.43% |
| Mar 31, 2024 | 6.31B | 1.18B | 22.97% |
| Mar 31, 2023 | 5.13B | 471.53M | 10.12% |
| Mar 31, 2022 | 4.66B | 383.28M | 8.96% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Morepen Laboratories | 18.06B |
| Hikal | 17.13B |
| TTK Healthcare | 8.57B |
| Venus Remedies | 7.70B |
| Lincoln Pharmaceuticals | 6.71B |
| Fredun Pharmaceuticals | 6.35B |
| Fermenta Biotech | 5.25B |
| Kwality Pharmaceuticals | 5.03B |